RBC Capital Markets increased its price target for Bio-Rad Laboratories to $440 from $390, while maintaining an 'Outperform' rating. This adjustment follows the company's strong Q3 2026 earnings report, which showed growth in both adjusted earnings and revenue, indicating positive analyst sentiment.
RBC Capital Markets raised its price target on Bio-Rad Laboratories (BIO) from $390 to $440, reaffirming an 'Outperform' rating. This positive adjustment is a direct response to the company's strong third-quarter 2026 earnings, which featured growth in adjusted earnings and revenue. This indicates a positive outlook from a major financial institution, potentially boosting investor confidence and short-term stock performance. For traders, this could signal continued upward momentum, though the long-term implications depend on sustained financial performance. The key opportunity is for investors to capitalize on this renewed analyst optimism.